Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

Trial Profile

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin detemir
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms Onset 1
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 08 Dec 2017 Results assessing long-term safety and efficacy of faster aspart in the additional 26-week period, presented at the 2017 Congress of the International Diabetes Federation.
    • 08 Dec 2017 Results of post hoc analysis was to investigate the impact of baseline body mass index (BMI) and HbA1c on glycaemic control presented at the 2017 Congress of the International Diabetes Federation
    • 08 Dec 2017 Results of post hoc analysis assessing the impact of the dose adjustment method on the efficacy and safety of mealtime fast acting insulin aspart and insulin aspart presented at the 2017 Congress of the International Diabetes Federation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top